Premium
Successful treatment of facial localized discoid lupus erythematosus with intralesional betamethasone: A report of three cases
Author(s) -
Liang JingYao,
Xiong QiYing,
Liang XiaoDong,
Deng Jie,
Ye RuiXian,
Liu HuanYan,
Dong LiangJiao,
Zhang XiBao
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13389
Subject(s) - medicine , discoid lupus erythematosus , dermatology , betamethasone , refractory (planetary science) , lupus erythematosus , atrophy , surgery , pathology , antibody , immunology , physics , astrobiology
Discoid lupus erythematosus (DLE) is a chronic autoimmune skin disease that usually causes disfiguring scarring, dyspigmentation, and atrophy. Despite a range of available topical and systemic therapies, the treatment of DLE remains a therapeutic challenge, especially in some refractory cases. Here, we reported three male patients with long‐term chronic lesions of unilateral facial localized DLE, who failed to have their disease controlled with many previous topical/systemic treatments, showed rapid and well response to intralesional injections of betamethasone (2 mg/mL, 0.2 mL/site) monotherapy once every 2 weeks for two, two, and four times of treatment, respectively. I ntralesional betamethasone may provide a safe and effective alternative in the management of refractory localized DLE skin lesions.